ARCA BIOPHARMA INC (ABIO)
US00211Y5069 - Common Stock
ARCA BIOPHARMA INC
NASDAQ:ABIO (8/30/2024, 8:00:00 PM)
After market: 2.48 +0.08 (+3.33%)2.4
-0.1 (-4%)
Company Profile
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The company is headquartered in Westminster, Colorado and currently employs 4 full-time employees. The company went IPO on 2000-07-21. The firm's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. The company is also evaluating options for development of its assets, including partnering and other strategic options.
Company Info
ARCA BIOPHARMA INC
10170 Church Ranch Way, Suite 100
Westminster COLORADO 80021
P: 17209402200
CEO: Michael R. Bristow
Employees: 4
Website: https://arcabio.com/
ABIO News
5 months ago - ARCA biopharma, Inc.ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock SplitThe combined company will operate as “Oruka Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “ORKA” effective Tuesday,...
5 months ago - ARCA biopharma, Inc.ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka TherapeuticsWESTMINSTER, Colo., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced an update to the previously announced...
5 months ago - ARCA biopharma, Inc.ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka TherapeuticsWESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced that its Board of Directors (the...
5 months ago - ARCA biopharma, Inc.ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka TherapeuticsSpecial dividend estimated to be $1.59 per share Payment of special dividend conditioned upon ARCA stockholder approval of the Proposed Merger with Oruka ...
6 months ago - ARCA biopharma, Inc.ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateWESTMINSTER, Colo., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a...
7 months ago - Halper Sadeh LLPSHAREHOLDER UPDATE: Halper Sadeh LLC Continues to Investigate ABIO, MODN, DPSI, AIRC/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
ABIO Twits
Here you can normally see the latest stock twits on ABIO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
